WallStSmart

Novartis AG ADR (NVS)vsOption Care Health Inc (OPCH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 898% more annual revenue ($56.58B vs $5.67B). NVS leads profitability with a 23.9% profit margin vs 3.6%. OPCH appears more attractively valued with a PEG of 1.17. OPCH earns a higher WallStSmart Score of 56/100 (C).

NVS

Hold

49

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

OPCH

Buy

56

out of 100

Grade: C

Growth: 5.3Profit: 6.0Value: 6.0Quality: 5.8
Piotroski: 3/9Altman Z: 2.84
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued
OPCHFair Value (-3.8%)

Margin of Safety

-3.8%

Fair Value

$33.39

Current Price

$20.51

$12.88 premium

UndervaluedFair: $33.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

OPCH2 strengths · Avg: 8.0/10
P/E RatioValuation
16.2x8/10

Attractively priced relative to earnings

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.223/10

Elevated debt levels

PEG RatioValuation
3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

OPCH4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.3%4/10

1.3% revenue growth

EPS GrowthGrowth
3.4%4/10

3.4% earnings growth

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bull Case : OPCH

The strongest argument for OPCH centers on P/E Ratio, Price/Book. PEG of 1.17 suggests the stock is reasonably priced for its growth.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Bear Case : OPCH

The primary concerns for OPCH are Revenue Growth, EPS Growth, Profit Margin. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

NVS profiles as a declining stock while OPCH is a value play — different risk/reward profiles.

OPCH carries more volatility with a beta of 0.65 — expect wider price swings.

OPCH is growing revenue faster at 1.3% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

OPCH scores higher overall (56/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Option Care Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.

Want to dig deeper into these stocks?